Study on How Being a Cystic Fibrosis Carrier Affects Kidney and Pancreas Health

What this Trial Is About

Researchers are studying whether carriers of the Cystic Fibrosis CF gene have a higher risk of developing certain pancreatic and kidney problems compared to people without the gene. This observational study aims to detect early signs of these disorders by comparing CF carriers and controls. The study is led by Philip Polgreen and involves one clinic visit and optional at-home sample collections. During the clinic visit, all participants will have measurements taken for height, weight, and blood pressure. They will undergo a 2-hour oral glucose tolerance test OGTT with several blood draws before, during, and after the test to measure glucose, insulin, and other related blood markers. Participants will also complete surveys about their health and medications. A smaller group of volunteers may collect urine and stool samples at home and return them for lab testing. Participants will be involved in one clinic visit lasting about 3 to 4 hours, during which they will complete surveys and provide blood samples. Volunteers collecting urine and stool samples will follow instructions at home and return the samples later. Researchers will compare glucose and insulin levels as primary outcomes, along with other markers like C-reactive protein, lactoferrin, calprotectin, and lipid values. The study will monitor these results to better understand the health risks for CF carriers.

The Effects of the CF Carrier State on the Kidneys and Pancreas